Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Crucell Terug naar discussie overzicht

Next generation vaccine maker

13 Posts
| Omlaag ↓
  1. wilb52 29 november 2005 07:17

    • wilb52

      Lid sinds: 01 jan 2000

      Laatste bezoek: 08 jul 2022

    • Aanbevelingen

      Ontvangen: 1701

      Gegeven: 224

    •    Aantal posts: 5.104

    Vaccine maker seeks faster production method
    Dutch firm using next-generation technology to tackle age-old problem
    Related Stories | What's this?
    • New vaccine method may help fight bird flu
    • Inhaled bird flu vaccine in the works
    • Bird flu questions and answers
    • U.K. plans mass vaccination against bird flu
    • Change to flu vaccine production proposed



    By Mike Huckman
    Reporter
    CNBC
    Updated: 5:58 p.m. ET Nov. 28, 2005


    Mike Huckman
    Reporter

    --------------------------------------------------------------------------------

    • Profile


    With a vaccine industry that’s been dormant for decades, fears of a pandemic avian flu outbreak have re-ignited the race for protection against the deadly disease.

    Now, one Amsterdam-based company is using next generation technology to tackle an age-old problem.

    Medicine has come a long way since newsreels about the 1957 flu pandemic touted the latest vaccines “produced at the highest rate possible through the standard slow method of incubating the virus in eggs."
    But in many respects, vaccine production is still stuck in the 1950s. So President Bush is offering the drug industry a nearly $3 billion shot in the arm to rocket vaccine science into the future.

    "By bringing cell-culture technology from the research laboratory onto the production line,” Bush said in a Nov. 1 speech to the National Institutes of Health, “we should be able to produce enough vaccine for every American within six months of the start of a pandemic."

    That may be so, but only if a pandemic is years away.

    Many experts and investors consider the Netherlands-based biotechnology company Crucell to be at the forefront of cell-based vaccine technology. But company chief executive Dr. Ronald Brus says his firm isn't even close to being ready to crank out the hundreds of millions of shots a year needed for a pandemic.

    "A best case scenario at this moment in time -- and I don't want to be overly optimistic -- would still be a three-year timeframe,” he said in a recent interview with CNBC.

    Crucell and its flu vaccine partner, Sanofi Aventis, recently won a nearly $100 million grant from the National Institutes of Health to speed things along.

    That money, plus more cash from Sanofi, puts Crucell in the unusual position of being able to plow all of its revenue straight into research and development.

    The company used to have just three people working on the flu vaccine project in its labs outside Amsterdam. Today there are 40 taking old human cells from the retina and feeding them so they can multiply in this chamber. The cells are then stockpiled so there's enough experimental flu vaccine available for lab tests.

    Dr. Jaap Goudsmit, Crucell's Chief Scientific Officer, is confident the technology will work.

    "There's nobody doubting that ten years from now there will be no egg-based vaccine anymore,” he said. “it will be all cell-based."

    A so-called "clean room" at Crucell is actually filled with the flu. In fact, inside this freezer the virus is being stored at about 80-degrees below zero centigrade -- just waiting to be mixed with human cells inside this bioreactor.

    After the human cells and the virus are churned in here for just one to two weeks, the vaccine's finished. The old-fashioned way with eggs takes months.

    "So what we did is replace the chicken egg thing with a bioreactor,” said Brus. “And we could make faster, cleaner and much bigger quantities of the vaccine in a shorter period of time."

    Crucell is in the lead but is in a race against time with companies like Chiron and Novavax -- all working on different types of cell-based vaccine technology.

    Brus says he doesn't like to brag or boast but “we just got a beautiful set of cards, right. And we're playing a certain game… but we still need to win the game.”

    (CNBC's Steve Lewis contributed to this report.)

    link:http://msnbc.msn.com/id/10241921/

    sammie

  3. [verwijderd] 29 november 2005 08:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Beter laat dan nooit zullen we maar zeggen. Dit artikel geeft wel aan dat er op het vlak PUBLICITEIT nog flink wat koerswinst te halen valt. Ebola, Marburg, Westnile, malaria, HIV, TBC, rabies, SARS, EPO ?


  9. [verwijderd] 30 november 2005 08:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    upstream schreef:

    Heeft iedereen het bericht onderaan de tekst een rating gegeven, als er genoeg stemmen uitgebracht worden, dan komt het bericht onder "Top Rated" terug.

    www.msnbc.msn.com/id/10241921/
    _________________________________________________

    gedaan, teller nu op 53
    zie ook draadje "Rating artikel msnbc"...
    Groeten aan alle crucell-beleggers op dit forum.
    Joe
13 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.846
AB InBev 2 5.294
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.602
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 9.001
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 32
Adomos 1 126
AdUX 2 457
Adyen 13 16.557
Aedifica 2 832
Aegon 3.257 320.181
AFC Ajax 537 7.025
Affimed NV 2 5.769
ageas 5.843 109.781
Agfa-Gevaert 13 1.869
Ahold 3.536 74.004
Air France - KLM 1.024 34.370
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.778
Alfen 12 16.697
Allfunds Group 3 1.224
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 339
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.769
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.420
AMG 965 126.335
AMS 3 73
Amsterdam Commodities 303 6.524
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.177
Apollo Alternative Assets 1 17
Apple 5 322
Arcadis 251 8.627
Arcelor Mittal 2.024 318.728
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.156
Aroundtown SA 1 183
Arrowhead Research 5 9.295
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.736
ASML 1.762 77.307
ASR Nederland 18 4.138
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.700
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 14 mei

    1. B&S Group Q1-cijfers
    2. OCI Q1-cijfers
    3. Bayer Q1-cijfers
    4. Agfa-Gevaert Q1-cijfers
    5. Dui inflatie april (def)
    6. VK werkloosheid maart
    7. Dui ZEW-index economisch sentiment mei
    8. VS ondernemersvertrouwen MKB april
    9. Home Depot Q1-cijfers
    10. Maandrapport OPEC
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda